AstraZeneca has announced a restructuring programme designed to deliver benefits of about $1.5 billion, money it plans to plough back into developing new medicines as it pursues its ambition of generating $80 billion in annual revenue by 2030.
The Anglo-Swedish drugmaker said on Friday that the programme would support investment across its pipeline, including in cancer, obesity and rare diseases. It expects the restructuring to result in one-time charges of up to $2 billion and to be largely complete by the end of 2029.
The company did not say whether the plan would involve job cuts. That detail, often the most closely watched element of any large restructuring, was left unstated in the announcement, leaving employees and investors to await further specifics on where the savings will fall.
The announcement came alongside third-quarter results that surpassed analyst expectations, prompting the company to maintain its outlook for 2026. Shares in AstraZeneca rose 3.6% on Friday, helping lift London’s wider pharmaceutical sector.
Chief executive Pascal Soriot has been stepping up investment across therapy areas as he seeks to reassure investors that recent trial setbacks have not undermined the company’s long-term prospects. The savings drive is presented as a way to fund that ambition from within, rather than relying solely on revenue growth.
AstraZeneca is not alone in turning to cost savings to fund drug development. British rival GSK laid out a £1.9 billion ($2.54 billion) cost-savings plan in July, aimed at generating cash to fund its own pipeline and prepare for looming patent losses, a reminder of the pressure facing large drugmakers as older medicines lose exclusivity.
For AstraZeneca, the test will be whether the promised savings materialise on schedule and translate into the new treatments needed to hit its 2030 revenue target. Investors welcomed the plan on Friday, but the restructuring charges and the absence of detail on jobs mean scrutiny of its execution is only just beginning.
Sources: Reuters, “AstraZeneca kicks off $1.5 billion savings drive to invest in pipeline after sales beat” (30 October 2026), https://www.reuters.com/legal/litigation/astrazeneca-kicks-off-savings-drive-invest-pipeline-after-sales-beat-2026-10-30/ ; Reuters, “FTSE 100 set for monthly gains; AstraZeneca up after results” (30 October 2026), https://www.reuters.com/business/finance/ftse-100-set-monthly-gains-astrazeneca-up-after-results-2026-10-30/
